NCT05734872 (VR) is a NA clinical trial of Virtual Reality Technology in Non-suicidal Self-injury, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT05734872?

NCT05734872 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT05734872?

Interventions in NCT05734872: Virtual Reality Technology, Routine mental health course training.

What condition does NCT05734872 study?

NCT05734872 studies Non-suicidal Self-injury.

Is NCT05734872 still recruiting?

NCT05734872 is currently status unknown. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT05734872: VR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Research on the Intervention of VR-based Emotion Regulation Technology on Adolescent Non-suicide Self-injury Behavior

Status unknown NA Last updated 21 February 2023

What this trial tests

NA trial testing Virtual Reality Technology in Non-suicidal Self-injury in 60 participants. Status unknown.

Timeline

26 October 2022

Primary endpoint
26 December 2023

26 October 2024

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	26 October 2022
Primary completion	26 December 2023
Estimated completion	26 October 2024
Sites	1 location across China

Drugs / interventions tested

Virtual Reality Technology
Routine mental health course training

Conditions studied

Non-suicidal Self-injury — all drugs for Non-suicidal Self-injury →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 24, any sex, with Non-suicidal Self-injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Non suicidal self injury (NSSI) has become a serious social and public health problem allover the world, and the incidence rate is increasing year by year. Although the aim of NSSI is not to suicide, but its negative impact is extremely serious, which will seriously threaten the physical and mental health of adolescents. Virtual Reality (VR), a computer simulation technology, can enable people to enter and experience the artificial virtual world in an immersive way, has been used for the auxiliary treatment of anxiety disorder, post-traumatic stress disorder and other diseases. This study explored the impact of VR on the depression and mental health of NSSI adolescents, so as to reduce the incidence of non-suicide self-injury behavior in NSSI adolescent patients and improve the quality of life of such patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Virtual Reality Technology

Trials testing the same drug.

NCT06424093 — Effect of Virtual Reality Technology for Managment of Acute Pain in Outpatient Hysteroscopy · NA · recruiting
NCT03169374 — Virtual Reality for Anxiety Management in Mechanically Vented Patients · NA · completed

Other recruiting trials for Non-suicidal Self-injury

Currently open trials in the same condition.

NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting
NCT07152925 — The Impact of Beta-band Transcranial Alternating Current Stimulation (tACS) on Impulse Inhibition in Adolescents With No · NA · recruiting
NCT06106555 — Which Factors Are Relevant for Treatment Outcome in Dialectical Behaviour Therapy for Borderline Personality Disorder? · recruiting
NCT06424509 — Effects of Psychiatric Admissions on Self-harm and Suicide in People With Borderline Personality Disorder · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05734872 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05734872.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing